1. Home
  2. DBVT vs HUYA Comparison

DBVT vs HUYA Comparison

Compare DBVT & HUYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DBV Technologies S.A.

DBVT

DBV Technologies S.A.

N/A

Current Price

$9.02

Market Cap

692.2M

Sector

Health Care

ML Signal

N/A

Logo HUYA Inc. American depositary shares each  representing one ordinary share

HUYA

HUYA Inc. American depositary shares each representing one ordinary share

N/A

Current Price

$1.98

Market Cap

572.2M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
DBVT
HUYA
Founded
2002
2014
Country
France
China
Employees
90
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
692.2M
572.2M
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
DBVT
HUYA
Price
$9.02
$1.98
Analyst Decision
Buy
Buy
Analyst Count
7
10
Target Price
★ $36.51
$3.16
AVG Volume (30 Days)
300.2K
★ 779.4K
Earning Date
10-28-2026
11-17-2026
Dividend Yield
N/A
★ 6.46%
EPS Growth
★ 10.26
N/A
EPS
N/A
★ N/A
Revenue
★ $5,636,000.00
N/A
Revenue This Year
N/A
$8.00
Revenue Next Year
$1,837.59
$7.26
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 35.77
N/A
52 Week Low
$8.63
$1.94
52 Week High
$26.19
$4.93

Technical Indicators

Market Signals
Indicator
DBVT
HUYA
Relative Strength Index (RSI) 37.71 39.32
Support Level $8.78 N/A
Resistance Level $12.41 $2.55
Average True Range (ATR) 0.76 0.12
MACD -0.12 -0.01
Stochastic Oscillator 0.97 13.25

Price Performance

Historical Comparison
DBVT
HUYA

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

About HUYA HUYA Inc. American depositary shares each representing one ordinary share

Huya officially became independent in 2016 and is headquartered in Guangzhou. It operates a live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. Huya is a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power, as of the end of 2025.

Share on Social Networks: